PROPHYLACTIC ANTICRYPTOSPORIDIAL ACTIVITY OF ATORVASTATIN VERSUS NITAZOXANIDE ON EXPERIMENTALLY INFECTED IMMUNOSUPPRESSED MURINE MODELS

By

ASMAA M. FAROUK AL-GHANDOUR1*, ASMAA MOHAMMED YOUSEF1, RASHA M. S. M. MOHAMED2, AL-SAYED M. TEALEB5, HYTHAM K. AHMED4, HANAA A. ATWA3 and TAHANDI ISMAIL FARAG1

Departments of Medical Parasitology1, Clinical Pharmacology2, Pathology3, Clinical Pathology4, Faculty of Medicine, Zagazig University, Zagazig, and Department of Pathology5, Al-Azhar University, Cairo, Egypt (*Correspondence: amfahmy@zu.edu.eg)

Abstract

This study investigated the possible prophylactic and curative role of Atorvastatin (ATV) in treatment of cryptosporidiosis in immunosuppressed cases. Immunosuppression was done using oral dexamethasone (0.25μg/g/day) for 14 days before infection till last scarification. The study included 150 immunosuppressed mice in 5 major groups (N=30): G1: Normal control group, G2: Infected control group, G3: ATV (40mg/kg/day), G4: Nitazoxanide (NTZ; 500mg/kg/day), G5: combination group. Each one was divided into 3 subgroups of 10 mice each: prophylaxis ones received drug daily for 5 consecutive days before infection only, 1st and 2nd therapeutic dose groups: mice received the drug for 1 week and 2 weeks after prophylaxis and infection, respectively. Assessment was done parasitological by formol-ether concentration and Modified Ziehl-Neelsen staining of stool pellets gathered weekly, immunological by serum IFN-γ levels and histopathological by haematoxyline and eosin staining to determine the drug regimens and parasite impacts on tissues.

The results showed a significant reduction in inflammatory changes of ileum, stomach and liver histopathology and in oocysts shed on the 7th day post infection (PI) by 62.08%, 40.55% & 71.78%, on the 14th day (PI) by 78.53%, 53.4%, 87.43% & 90.41%, 57.21%, 94.71% on 21st day (PI) in all treated groups respectively, compared to infected untreated control ones. Sera IFN-γ levels showed significant increase in combination followed by ATV prophylactic drug regimens compared to NTZ alone or infected control ones. Combined ATV and NTZ prophylaxis gave a good synergistic anticryptosporidial efficacy in immunosuppressed mice.

Key words: Cryptosporidium, Atorvastatin, Prophylaxis, Nitazoxanide combination, immunosuppressed.

Introduction

Cryptosporidium species are well recognized as corporate causes of both water- and food-borne outbreaks of diarrheal illness around the world (Ryan et al, 2018). Livestock (mainly cattle) and wildlife (e.g. deer) were found to be pertinent donors to zoonotic Cryptosporidium oocysts in recreational and drinking water supplies. Exploring host-parasite relationship to better understand cryptosporidiosis and its defense within the host is a requirement to advance its stratagems for prophylaxis and treatment. Modern advances in the genetic diagnosis of Cryptosporidium combined with new in vitro and in vivo models gave a better awareness of these relations (Widmer et al, 2020). Pollok et al. (2001) reported that immunological control of cryptosporidial infection in mice depended mainly on CD4 + T cells and gamma interferon (IFN-γ) production.

A wide range of techniques are used to investigate the immune response to C. parvum infection and the host-parasite relationship. Studies on murine models face certain obstacles, as in discrepancy with neonatal models, adult immunocompetent mice are hardly infected with C. parvum and there was thus no suitable adult mouse model to study Cryptosporidium infection. Sateriale et al. (2019) isolated a line of Cryptosporidium tyzzeri, a species that naturally colonizes the small intestine of mice and is also genetically tractable with CRISPR/Cas9. With this new murine model and many transgenic mouse lines, it was easy to prove that inter-
feron γ is a key cytokine and the significant role of T cells as a backbone in the fight against infection in adult mice. Moreover, this study confirmed that primary infection gives protection against a homologous challenge, redirecting our target towards evolving a vaccine that prevents or prohibits the severity of cryptosporidiosis and to trail the progression of the Cryptosporidium life cycle controlled by stage-specific agents, such as promoters those are active during sexual differentiation and oocyst formation (Wilke et al., 2019).

All plastid-associated metabolic pathways in Cryptosporidium parasite as one of the apicomplexan family e.g.; Methyerythritol phosphate pathway- are missing; as they lost their apicoplast during development (Abrahamsen et al., 2004; Xu et al., 2004). Artz et al. (2008) reported that Cryptosporidium spp. genome has an entrance to isoprenoid precursors, by salvaging isoprenoids derived from isopentenyl-5- pyrophosphate (IPP) or other short to-medium-chain isoprenoids from the host as it has three prenyl synthases. A cell-based high-throughput screening (HTS) for anti-cryptosporidial agents; screening the NIH Clinical Collections libraries reported that statins were identified as a hopeful principal candidate with effective capability in inhibiting growth of Cryptosporidium spp.

Atorvastatin (ATV) was first approved in the UK as a synthetic statin that subsists in its active hydroxy-acid formula with pyrole based ring assembly (Davidson, 2002). HMG-CoA reductase inhibition held by ATV and its family in the host liver is well tolerated in man; this made the statins an excellent applicant for repurposing as an anti-cryptosporidial agent.

Nitazoxanide (NTZ, Alinia; Romark Laboratories L.C., Tampa Florida, USA); licensed by the U.S. Food and Drug Administration (FDA) for the treatment of cryptosporidiosis in immune-competent, but unfortunately it gave unsatisfactory effects in immunosuppressed even after several week (100 mg/kg/day) therapy confirmed by nested-PCR technique (Atia et al., 2016).

No available information concerning the efficacy of HMG-CoA reductase inhibitors and its combination with FDA-approved anti-parasitic Nitazoxanide drugs prophylaxis on liver tissue and biliary tract in cryptosporidiosis of immunosuppressed patients (Taha et al., 2017).

The work aimed to assess the prophylactic efficacy and therapeutic of Atorvastatin (ATV) versus high dose Nitazoxanide and their dual role on cryptosporidiosis in experimentally immunosuppressed mice.

**Materials and Methods**

Mice and immunosuppression: One hundred and fifty laboratory-bred, clean, male, Swiss albino mice, 10 weeks old and weighing 25-30g, were used. They were kept in the animal house and white wood chips for bedding. At Parasitology Department, Zagazig University Hospital; mice were fed by a commercial complete food mixture and previously boiled-tap water for drinking, and maintained under controlled environment with average temperature (25±2ºC) and standard light-dark cycle throughout the experimental period. This experiment was carried out according to the Clinical and Laboratory Standards Institute (CLSI) guide-lines, and was approved by the ethical committee of Zagazig University Hospitals.

All mice were immunosuppressed by oral administration of Dexamethasone at a dose of 0.25 µg/g/day for 14 days before infection; Dexazone (0.5mg) orally (Kahira Pharmaceuticals and Chemical Industries Company, Egypt). The mice continued to receive dexamethasone at the same dose throughout the study (Rehg et al., 1988).

Mice were divided into five groups (G), 30 mice each; G1 was non-infected-non treated (negative control), G2 was infected-non treated (positive control), G3 was treated by Atorvastatin alone (ATV 40 mg/kg/day), G4 was received NTZ (500mg/kg/day-bid-); (drug control), and G5 was treated by Atorvastatin combination (ATV 40mg/kg/day +
Prophylaxis, Infection & therapy: Prophylaxis was done for 5 days before infection for the last 3 groups; either by Atorvastatin alone (ATV 40 mg/kg/day) or NTZ (500 mg/kg/day-bid) or their combination (ATV 40 mg/kg/day+ NTZ 500mg/kg/day-bid) respectively. Infection was done by inoculation of G2, infected control group+ G3,G4, & G5 prophylactically treated groups of mice intraoesophagealy with 0.1ml of Cryptosporidium oocysts inoculum (3x10⁶ oocysts /ml) (Benamrouz et al, 2012).

Cryptosporidium oocysts were obtained from Pediatric Oncology Department diarrheic children. The stool samples were collected in sterile clean stool cups without contaminated water or urine. After collection of stool samples, oocysts were purified (Arrowood and Donaldson 1996). Purified oocysts were kept in 2.5 % potassium dichromate solution and stored at 4 °C until required. Infective inoculum was prepared and the number of oocysts in the concentrated stock inoculum was counted to determine the inoculum per mouse (Reese et al, 1982). Mice feces were examined daily for oocysts recovery to confirm infection, which was recovered after 3-5 days. Fecal pellets were collected and parasitologically examined using formol-ether concentration and the Modified Ziehl-Neelsen stain to count the number of Cryptosporidium oocysts (Casemore et al, 1985). The number of parasites was expressed per gram of feces (Benamrouz et al, 2012).

The efficacy percentage of each drug was calculated using the equation: Efficacy (%) = mean value of infected untreated group - mean value of infected treated group x100 / mean value of infected untreated group (Hosking et al, 1996).

Histopathological drug evaluation: The ileocecal junction, stomach and liver tissues were excised, and opened longitudinally, oriented on a filter paper and fixed in 10% formalin. After fixation, the tissues were processed for paraffin embedding. Sections of 4μm thickness were stained with haematoxyline and eosin (H&E) stain and examined for pathological changes (Drury and Wallington, 1980).

Determination of interferon gamma (IFN-γ) levels in mice sera: Blood samples were with-drawn at the scarification time in plain
tubes. Sera were separated by left blood at room temperature for 30 minutes, centrifuged at 3000rpm for 15min. aliquoted and stored at -20ºC. IFN-γ concentrations were assayed by double-sandwich ELISA kit after the manufacturer’s instructions (Bioneovan Co, Ltd, Beijing, China). Optical density values were measured at 450nm & 630nm filters. Concentrations of IFN-γ were determined from standard curve with 3pg/ml - 200pg/ml assay ranges.

Statistical analysis: Data were presented as mean and SD and determined by two-way ANOVA, followed by a post hoc Bonferroni test, one-way ANOVA with Tukey's Multiple Comparison Test, unpaired Student’s t-test for selected pairs of data using Graph Pad Prism version 5 (Graph Pad Software). P values < 0.05 were considered significant, Significant P value<0.05 and highly significant P <0.001 (Peat and Barton, 2005).

Ethical consideration: The study was conformed to the Guide for the Care and Use of Laboratory Animals published by the US NIH (No. 85-23, revised 2011)

Results

Oocysts reduction: C. parvum oocysts were counted in stool pellets of immunosuppressed mice after 5-7 days PI (7th day), then 5-7 days of 1st dose therapy (14th day), and lastly after 7 days of 2nd dose therapy (21st day). Atorvastatin (ATV 40mg/kg/day) reduced Cryptosporidium oocysts number in infected mice when used as prophylaxis alone or prophylaxis followed by treatment after infection compared to NTZ (500mg/kg/day) alone and their combination dual efficacy. Oocysts in infected control mice (G2) decreased (G2a) from (185700±45114.12) on 7th day to (177600±1502.223) in (G2c) on 21st day P.I. Prophylactic treatment of infected mice by ATV40 in (G3a) significantly reduced the mean Cryptosporidium oocysts clearance (P < 0.0001) with (62.08%) efficacy, while dual PX (G5a) (ATV40+ NTZ500) was (71.78%) compared to NTZ prophylaxis alone (G4a) was (40.55%). In the 1st dose therapy after PX (14th day P.I), ATV40 in (G3b) had (78.53%) efficacy that reached (90.41%) in 2nd week therapy after PX (G3c) compared to (53.4%) & (57.21%) in NTZ alone (G4b, c, respectively). The best efficacy was by dual therapy after PX (ATV40+NTZ 500), to (87.43%) at 14th day PI (G5b), and (94.71%) at 21st day PI. (G5c).

Comparison between each regimen in the three prophylactic period of 1st & 2nd booster therapeutic doses and corresponding infected control one (Fig.1) showed very high significant reduction of oocysts counts in all prophylactic treated groups as compared to positively infected ones, with significant difference between oocyst reduction of NTZ & ATV groups in prophylaxis and 1st week therapy after that only.

Histopathological examination of ileal mucosa of Cryptosporidium infected mice revealed profound histopathological changes in the intestinal mucosa as a result of infection with Cryptosporidium oocysts in the form of villous atrophy, inflammatory cellular infiltrate. Some cases revealed nuclear changes and dysplasia (increased Nuclear/cytoplasmic ratio, pleomorphism, prominent nucleoli, and frequent mitotic figures) with intra epithelial inflammatory cells with eosinophils. ATV-treated group showed mild inflammatory cellular infiltrate or nearly normal ileal tissue in comparison to infected untreated group or drug control therapy while, the combination regimens showed normal appearance with minimal inflammatory cells and pathological changes.

Histopathological examination of ileum showed mild to moderate inflammation, edema, low grade dysplasia, tissue necrosis and sloughing as well as oocysts, but treated ones showed marked inflammation and dysplasia improvement. ATV-treated group showed mild inflammatory cellular infiltrate or normal gastric tissue as compared to infected untreated group or drug control therapy while, the combined regimens had better outcome as compared to ATV treated ones after prophylaxis with minimal inflamma-
ry cells and pathological changes.

Histopathological examination of liver tissue showed infiltration by oocysts with inflammatory cells within portal tract and hepatic lobules, associated with dilated sinusoids, vacuolated cytoplasm, focal necrosis, apoptosis, and bile duct proliferation were focally in few cases. Large cell dysplasia occurred in some cases. The inflammation ranged from mild, moderate to severe inflammation. ATV alone and combined regimens showed mild inflammation to normal liver tissue architecture.

IFN-γ levels were highly significantly increased after Atorvastatin prophylaxis (G3a: ATV40-PX) (7th day P.I) reached (21±0.95) compared to the infected G2a (15.7±0.87) (P <0.0001) with T-test (13.01). In G3b, after prophylaxis, infection and 1st dose therapy by (ATV40) (14th day P.I), IFN-γ level was more significantly increased to (72.9±0.89) compared to infected G2b (P <0.0001) (14.8±0.80) with T-test (153.5). G3c after prophylaxis and 2nd dose therapy with (ATV40; 21st day P.I), IFN-γ level was significantly increased highly to (77.9±0.89) compared to G2c (P <0.0001) (13.8±0.80) with T-test (162.3) (Fig. 2).

At 14th day PI, mean IFN-γ level in (G4a) NTZ prophylaxis group was (16±1.02) without significant (P >0.05) and T-test (0.7076) compared to infected G2a (15.7±0.87). In G4b, after prophylaxis & 1st week NZT therapy (21st day PI), mean IFN-γ level to (19.3±0.63) with a high significant (P <0.0001) compared to G2b and T-test (13.97), but in subsequent 2nd week therapy G4c (28th day PI) reached (24.2±1.10) with a high significant (P <0.0001) compared to infected G2c and T-test (24.36). In combined ATV40+NTZ 500, IFN-γ levels in prophylaxis G5a showed a significant increase (24.2±1.08) compared to infected G2a (P<0.0001) with T-test (19.38). In G5b after prophylaxis and 1st dose therapy, IFN-γ levels showed more significant increase (47.3±0.91) compared to infected G2b (P <0.0001) with T-test (84.82).

In 2nd dose after PX IFN-γ levels reached (81.4±0.85) with highest significant increase (P <0.0001) compared to G2c with T-test (175) (Fig. 2).

**Discussion**

Watery diarrhea and malabsorption were symptoms linked to sodium malabsorption, electrogenic chloride secretion, and increased intestinal permeability associated with cryptosporidiosis (Zhang et al, 2000). Some neuropeptides e.g. substance P and host immune response itself were the main sponsors for these effects (Pantenburg et al, 2008). Checkley et al. (2015) thought that ileitis by cryptosporidiosis is the main contributor of the bad impacts on its host overall health with the impaired absorption and copious secretions indorsing diarrheal disease, most aggravated in children and immunosuppressed patients. They concluded that the imperative anticryptosporidial target that restores the small intestinal villi integrity reflected considerable impact on human’s health.

Nitazoxanide (NTZ), a nitrothiazole salicylate derivative, absorbed from the gastrointestinal tract advisable during taking meal, is active on bacteria as *Helicobacter pylori* and a broad spectrum of helminths as *Taenia saginata*, *Hymenolepis nana*, *Fasciola hepatica* and protozoa as *Isospora belli*, *Entamoeba histolytica*, *Giardia lamblia* and *Enterocytozoon bieneusi* (Rossignol and Maisonneuve, 1984; McVay and Rolfe, 2000; Bicart-See et al, 2000).

Nitazoxanide is the only proven anti-parasitic treatment for cryptosporidiosis by FDA, despite its low efficacy in immunocompromised cases, which restricted choices treatment grants a foremost public health contest assuming the significant load of disease in immunosuppressed (Sparks et al, 2015 and Atia et al, 2016).

Li et al. (2003) in an immunosuppressed rat was studied the long-lasting anti-cryptosporidial activity of nitazoxanide in comparison with sinefungin (SNF) and paromomycin (PRM) showed that NTZ at either 50mg/kg/day, 100mg/kg/day or 200mg/kg/day, in seven days duration gave a dose-dependent
reduction in oocyst shedding as with SNF (10mg/kg/day) and PRM (100mg/kg/day). The stoppage of SNF or PRM 100mg/kg/day therapy led to early relapse of oocyst clearance that returned to pre-treatment levels in 2-4 days, with unchanged data after seven days stoppage of NTZ therapy, recommended more assessment of NTZ activity on sequestered *C. parvum* for longer durations in immunosuppressed models.

Others preferred combined therapies to eradicate cryptosporidiosis especially in immunocompromised & HIV patients (Giacometti *et al.*, 2000). There was sustained attention to improve therapies for this infection. Huwiler and Pfeilschifter (2009) showed the capability of lipid species as signaling molecules controlling the magnitude of cellular responses as cell growth, apoptosis and inflammatory reactions. Statins are well-known as cholesterol biosynthesis (steroid biosynthesis) inhibitors in humans by 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA reductase) inhibition. This enzyme has a beneficial role in regulating the mevalonate pathway, which produced cholesterol beside heme-A, coenzyme Q10 and isoprenylated proteins (Callegari *et al.*, 2010; Taha *et al.*, 2017). Statins occluded the intracellular transfer when stopped formation of isoprenoid (IPP) intermediates (Zhou and Liao, 2009).

Dinesh *et al.* (2014) studied the Atorvastatin and Simvastatin anti-leishmanial activity and proved their mechanisms via inhibition of HMG CoA reductase enzyme. *Cryptosporidia* with different genomes e.g. *C. parvum* and *C. hominis* genomes as members of the apicomplexan parasites are characterized by utilization of isoprenoids derived from IPP and dimethyl-allyl pyrophosphate (DMAPP) in one or more pathways as detected by the bioinformatics analysis of *Cryptosporidium* spp. genomes, despite we couldn’t confirm their ability to synthesis their own IPP or DMAPP independent on their host (Bessoff *et al.*, 2013). In accordance with this study results, prophylactic dose that preceded experimental cryptosporidial infection and the two booster therapeutic doses of Atorvastatin (40mg/kg) had enhanced a high significant oocyst reduction (62.08%) when used alone or in combined regimen (71.78%) and when the drug control group by Nitazoxanide (500mg/kg) used alone (40.55%) as compared with the infected control groups with duration-dependent increase in clearance of oocysts from stools. This agreed with Taha *et al.* (2017) who proved the therapeutic role of atorvastatin in cryptosporidiosis challenged infection in immunocompromised rats. They tested the therapeutic efficacy of 2 different doses of ATV (20 & 40mg/kg) alone and when combined with NTZ (1000 mg/kg) in treatment of cryptosporidiosis experimental infection. The study showed valuable oocyst reduction in (ATV+NTZ) combination as compared with infected, and drug controls and with that of 40mg & 20 mg ATV drug regimens at the 21st day PI; respectively. Basyoni *et al.* (2018) found that dose-dependent efficacy of ATV (20-40 mg/kg) either alone or in combination with Metronidazole (10mg/kg) in experimentally Blastocystis-infected mice caused the highest reductions in Blastocystis shedding.

Statins induced inhibition of cysteine protease and protected endothelial barrier integrity (Mirza *et al.*, 2012). Abdin *et al.* (2012) proved the valuable role of statins as antioxidants and anti-inflammatory agents beside their cholesterol-lowering activity. The present results agreed with Soliman and Ibrahim (2005) who interpreted the exaggerated apoptotic changes in *Cryptosporidium* infected groups and the exposure to combination therapy of ATV (40mg/kg) and NTZ (500mg/kg) by having the advantage of dual effects of ATV in healing epithelial tissues and targeting *Cryptosporidium*.

Higher doses of HMG-CoA reductase inhibitors were tested with antimalarial drugs (Wong and Davis, 2009); on *Babesia divergens* (Grellier *et al.*, 1994), *Plasmodium falciparum* (Pradines *et al.*, 2007), and also on *Toxoplasma gondii* growth (Cortez *et al.*, 2014).
2009) in vitro and gave valuable inhibitory effects on these coccidian protozoa. Nevertheless, in-vivo studies showed that statins inhibited the growth of both Trypanosoma procyclic and epimastigote forms (Coppens et al, 1995), and increased animals’ survival via inhibition of proliferation of more than 50% of Toxoplasma gondii in macrophages in a dose-dependent manner (Nishikawa et al, 2011; Li et al, 2013). Also, Atorvastatin showed tegumental modifications in S. haematobium adults with significant reduction in its burden and egg load (Soliman and Ibrahim, 2005). Zhao et al (2006) found direct and indirect antioxidant capabilities of statins to remove aged LDL, reduce reactive oxygen species and good effects in cardi-vascular diseases due to lipid lowering activity.

In this study, stained sections showed different inflammation degrees, and was classified based on cellular infiltration heaviness and presence of lymphocytic aggregation into mild, moderate and severe (Dieleman et al, 1998). Decreased ratio of villous height to crypt length, goblet cell depletion, lamina propria showed oedema with diffuse loss of brush border microvillous surface area. Atorvastatin prophylaxis resulted in upgrading partial improvement in such changes compared to drug control, with marked improvement in combined prophylactic therapy with mild inflammatory changes approaching to normal gastric and ileal mucosa due to partial healing and restoration of the villous architecture. This was agreed with Taha et al. (2017) who found good improvement of combined treated groups without prophylaxis with 20 or 40mg/kg/ day doses of ATV combined with NTZ (1000mg/kg/day). In this study, moderate gastritis of infected untreated mice with moderate inflammatory infiltration and edema occurred. Combined regimens showed remarkable improvement with normal gastric tissue, and ATV alone showed mild gastritis. Sections of NTZ treated group didn’t show a significant improvement with persistent moderate gastritis. Also, infected liver tissue in NTZ and ATV treated groups showed portal tract expansion by fibrosis, moderate inflammatory infiltrate and bile duct proliferation. Also, combined treated group after PX showed mild inflammatory cellular infiltrate within portal tract and hepatocytes markedly infiltrated by inflammatory cells with dilated sinusoids.

In this study, immunosuppressed infected mice shed oocysts in stool with significant serum IFN-γ reduced levels compared to normal control non-infected one. This agreed with Beardsley et al. (2018) who found that dexamethasone reduced the body production of IFN-γ led to worse cryptococcal meningitis and high mortality. The IFN-γ is one of the key body defense mechanisms against cryptosporidiosis (Gomez et al, 1996; Lacr-oix et al, 2001). Hayward et al. (2000) reported that IFN-γ protected immunodeficient mice from death from cryptosporidiosis.

In the present experiment, immunosuppressed mice experienced significant time dependent decrease in the number of shed oocysts in stool pellets with significant time dependent increase in IFN-γ compared to NTZ treated one. This agreed with Bessoff et al. (2013) who found potent inhibitory action (HMG-CoA) reductase inhibitor (ita-vastatin) on C. parvum growth. Also, Amadi et al. (2009) found that NTZ couldn’t eradicate Cryptosporidium infection in children with HIV immunosuppression. Anti-crypto-sporidial effect of NTZ depended on IFN-γ using an anti-IFN-gamma conditioned SCID mouse model (Theodos et al, 1998). Combined prophylaxis and treatment of immunosuppressed mice with atorvastatin and NTZ exhibited good synergistic prophylactic effect on eradication of oocytes, with the highest reduction percentage than either one alone. This agreed with Taha et al. (2017) who found synergistic role of atorv-astatin & NTZ in treating Cryptosporidium in immunosuppressed mice that showed significant time dependent increase in IFN-γ serum to normal level. Alber et al. (2006) found that atorvastatin has anti-inflammatory effect in atherosclerosis without affecting IFN-
Conclusion

Atorvastatin and high dose NTZ were used as prophylactic regimens to ameliorate the immune status and severity of cryptosporidiosis on immunosuppressed or lower heavy oocysts shedding. Atorvastatin gave progressive decline in oocyst excretion after PX with subsequent therapeutic dose that was more aggravated by synergistic combined with high prophylaxis Nitazoxanide dose. Molecular or ultrastructure study to clarify the effective prophylactic dose regimen is ongoing and will be published in due time.

Conflict of interest

The authors declared that they neither have any interest nor received fund.

References


Abdin, AA, Abd El-Halim, MS, Hedeya, SE, El-Saadany, AAE, 2012: Molecular and ultrastructure study to clarify the effective prophylactic dose regimen is ongoing and will be published in due time.

Conflict of interest: The authors declared that they neither have any interest nor received fund.

References


Li, ZH, Ramakrishnan, S, Striepen, B, Moreno, SNJ, 2013: Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin. PLoS. Path. 9, 10:e1003665.


Peat, J, Barton, B, 2005: Medical statistics: A
guide to data analysis and critical appraisal. 1st Ed. Oxford: Blackwell Publishing Ltd.


Explanation of figures

Fig.1: Experimental design of study.

Fig.2: A- Oocyst count: gm stool, comparison between each drug regimen in three time periods of prophylaxis, 1st & 2nd booster therapeutic doses (T-test). B-IFN-γ Concentrations (pg/ml) in mice sera (M±SD) between each regimen in three time prophylaxis periods, 1st & 2nd booster therapeutic doses by (T-test). C- Cryptosporidium oocyst in stool sample stained by M Z-N stain (x1500).

Fig. 3: H&E staining of Ileal mucosa for all groups 7th, 14th & 21st days PI. A-Normal control group showed normal ileal mucosa (x100). B- ATV Prophylaxis showed ileal mucosa with high grade dysplasia with frequent mitosis (x100). C- NTZ prophylaxis showed ileal mucosa with high grade dysplasia with frequent mitosis (arrows). D- Combination (ATV & NTZ) prophylaxis showed ileal mucosa with mild inflammation (arrows) and oocyst (x1000). E- Infected immunosuppressed control group (14th day PI) showed ileal mucosa with high grade dysplasia and oocysts surrounded by clear halo in brush border of ileal villi (x1000). F- ATV 1st week treatment after prophylaxis group
shows small intestinal submucosa infiltrated by moderate inflammatory cells (x1000). G- NTZ 1st week treatment after prophylaxis showed oocysts (arrow) surrounded by clear halo in ileal villi brush border (x1000). H- Combined group 1st week after prophylaxis showed ileal submucosa infiltrated by mild inflammatory cells (x1000). I- Infected immunosuppressed control group (21st days PI) showed ileal mucosa with high grade dysplasia and two oocysts (arrows) surrounded by clear halo (x1000). J- ATV 2nd week treatment after PX showed small intestine with lamina propria infiltrated by mild to moderate inflammatory cells (x1000). K- NTZ 2nd week treatment after PX showed small intestine with submucosal infiltration by extensive number of inflammatory cells (x1000). L- Combined group 2nd week treated group with ATV 40 after PX: showed ileal mucosa with mild inflammatory cells in lamina propria (x400).

Fig. 4: H & E staining of gastric mucosa for all groups 7th, 14th & 21st days PI. A- Normal control group showed gastric mucosa with normal histology (x400). B- Infected control group showed gastric mucosa infected by multiple Cryptosporidium oocysts, (arrows) surrounded by clear halo (x1000). C- ATV prophylaxis showed gastric mucosa infected by oocysts, arrow surrounded by clear halo (x400). D- NTZ PX group showed gastric mucosa with low grade dysplasia with mitosis encircled (x400). E- Combined PX showed gastric mucosa with edema in lamina propria (x400). F- ATV 1st week treatment after PX showed necrotic gastric mucosa with multiple oocysts, surrounded by clear halo (x400). G- NTZ 1st week treatment after PX showed gastric mucosa with low grade dysplasia and oocysts arrow (x400). H- Combination 1st week treatment after PX showed gastric mucosa with moderate inflammation lamina propria histology (x1000). I- ATV 2nd week treatment after PX showed gastric mucosa with normal histology with edema in muscle layer encircled (x400). J- NTZ 2nd week after prophylaxis showed moderate dysplasia of gastric epithelium (x1000). K- Combined group 2nd week treatment after prophylaxis showed gastric mucosa with normal histology with edema in muscle layer encircled (x1000).

Fig. 5: H & E staining of liver tissue for all groups 7th, 14th & 21st days PI. A- Normal hepatocytes arranged in cords, with normal sinusoids (x400). B- Infected control group showed liver tissue infected by Cryptosporidium oocysts showed portal tract expansion by inflammatory cellular infiltrate (black arrow) and bile duct proliferation (x400). C- ATV group after PX: Liver tissue showed moderate inflammation in portal tract (x100). D- NTZ prophylaxis group showed large cell dysplasia of liver tissue and focal necrosis (x400). E- Combination group after PX: Liver tissue showed portal tract with moderate inflammation (x400). F- ATV 1st week treated group after PX showed liver tissue infected by oocysts showed mild portal inflammation and cytoplasmic vacuolation (x100). G- NTZ 1st week treatment after PX: liver showed dilated portal tract with severe inflammation (x400). H- Combination 1st week treated group after PX shows Liver tissue showing dilated sinusoids arrow (x400). I- ATV 2nd week treated group after PX: Liver tissue showed focal necrosis of hepatocytes encircled with large cell dysplasia (x100). J- NTZ 2nd week treated group after PX: Liver tissue showed marked vacuolated cytoplasm encircled and moderate inflammation (x400). K- Combination 2nd week treated group after PX: Liver tissue showed mild to moderate portal tract inflammation.